Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 7fludarabine phosphate 5tanespimycin 4Cyclosporine 4Vincristine 3Peripheral Blood Stem Cell Transplantation 3Irinotecan 3Doxorubicin 3Bortezomib 3Antilymphocyte Serum 3nelarabine 2laromustine 2fludarabine 2entinostat 2belinostat 2alvocidib 2Vorinostat 2Psychiatric Rehabilitation 2Prednisone 2Pharmacogenomic Testing 2Oxaliplatin 2Mycophenolic Acid 2Methylprednisolone 2Magnetic Resonance Spectroscopy 2MLN 8237 2Levofloxacin 2Lenalidomide 2Gemcitabine 2Flow Cytometry 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Immunoblastic Lymphadenopathy × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡